Newland Pharmaceutical Co Ltd. Stock Analysis 301277.SZ

Newland Pharmaceutical Co., Ltd. engages in the research, development, production, and sales of chiral pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company is headquartered in Xuchang, Henan and currently employs 981 full-time employees. The company went IPO on 2022-11-16. The firm mainly operates three businesses. The pharmaceutical intermediates business mainly includes the L‑p‑hydroxyphenylglycine series and p‑toluenesulfonic acid. The active pharmaceutical ingredient business primarily includes lidocaine hydrochloride, naphazoline hydrochloride, vildagliptin, lidocaine, moxifloxacin hydrochloride, esomeprazole magnesium, tadalafil, ropivacaine hydrochloride, esomeprazole sodium, etomidate, and chlorpheniramine maleate. The pharmaceutical preparations business primarily includes vildagliptin tablets, moxifloxacin hydrochloride tablets, moxifloxacin hydrochloride sodium chloride injection, and ruxolitinib phosphate tablets. The firm primarily operates in the domestic market.